Register for our free email digests:
Latest From AvidBiotics Corp.
There is growing interest in the gut microbiome as a source of new therapies across a wide range of diseases. Although it is still an emerging field, pharmaceutical firms and other investors are engaging, with more expected to follow.
Advances in high-throughput screening and metagenomic data analysis have already helped uncover the microbiome’s potential as a source of new therapeutic approaches. But more new tools will be needed to further decipher it.
Anti-infective start-ups getting funded these days say they can boost the odds of clinical success, and reduce the cost of achieving it. Profiles of EnBiotix, Nosopharm, and Spero Therapeutics.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
- Large Molecule
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- AvidBiotics Corp.
- Senior Management
David W Martin, Chmn. & CEO
James L Knighton, Pres.
- Contact Info
Phone: (650) 615-7512
230 East Grand Ave
So. San Francisco, CA 94080
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.